18H04794), the Naito Foundation, a research grant from the Princess Takamatsu Cancer Research Fund 15-24728, the Uehara Memorial Foundation, and Japan Agency for Medical Research and Development (JP19gm5010002)
Annu Rev Physiol (2014) 76:53559
N Engl J Med (2022)
Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage
"Compounded semaglutide may carry additional risks and side effects beyond those seen with FDA-approved versions," explains Eapen, MD
Zhu Y, Tian J, Wei X, Jia S, Shu Q